Osivax publishes positive results from trial of influenza vaccine candidate
Ella Day | July 15, 2025 | News story | Research and Development | Osivax, Vaccine, Virology, clinical trial, influenza, respiratory diseases
French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, its broad-spectrum influenza vaccine lead candidate. The results have been published in the journal, Vaccines.
In the study, 180 healthy adults aged 18 to 55 years were given either Fluarix Tetra (hemagglutinin antigen-based inactivated influenza vaccine) with a placebo, Fluarix Tetra and OVX836, or OVX836 and placebo.
Based in Australia, the study demonstrated that the candidate induced complementary immune responses, as well as a favourable safety profile, both when administered alone or in combination with Fluarix Tetra.
“The favourable safety profile and strong immune response observed in this study provide encouraging evidence that OVX836 can be co-administered with a standard seasonal influenza vaccine,” commented Nicola Groth, chief medical officer of Osivax.
“The data collected will support the continued development of OVX836 as we focus on a single-injection formulation that streamlines vaccination delivery and maximises public health impact,” added Alexandre Le Vert, CEO and co-founder of Osivax.
Osivax develops vaccines to provide broad-spectrum protection against highly mutating infectious viruses using its oligoDOM nanoparticle platform technology. Its ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of COVID-19, both respiratory diseases, in one single vaccine.
Ella Day
15/7/25
Related Content
BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …
Chiesi expands La Chaussée-Saint-Victor site to manufacture next-gen inhalers
Chiesi, a biopharma group focused on treating respiratory diseases, has inaugurated an expansion of its …
Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …
